Jim Champagne has joined InSite One as senior vice president. Champagne will lead the development of new strategic goals and directions for the company, which specializes in the development and marketing of digital archives for medical imaging. New
Jim Champagne has joined InSite One as senior vice president. Champagne will lead the development of new strategic goals and directions for the company, which specializes in the development and marketing of digital archives for medical imaging. New initiatives for InSite One are targeting reseller and dealer distribution partners and channels, along with offering scalable archiving models. Champagne began his career with Philips Medical Systems, focusing on business development and marketing initiatives for PACS, computed radiography, and teleradiology. Most recently, he served as vice president of sales and business development for Konica Medical Imaging.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 2
July 25th 2025In the second of a multi-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, share their perspectives on remote MRI safety protocols for ensuring screening accuracy and adherence to conditional implant guidelines as well as a rapid and effective response to adverse events.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 2
July 23rd 2025In the second part of a multi-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, discuss key sequences for abbreviated breast MRI and how it stacks up to other breast cancer screening modalities.
Chest CT for Post-COVID-19 Abnormalities: Nine Takeaways from a Multi-Society Consensus Statement
July 22nd 2025Developed by 21 thoracic radiologists, the new international consensus statement addresses appropriate indications, scan acquisition and keys to reporting for the use of chest CT imaging in evaluating for residual lung abnormalities from COVID-19.